{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032536","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.478235+00:00","generated_at":"2026-06-21T18:33:00.604433+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PAVmed Q3 net loss $26.2M ($0.29/sh); EsoGuard volumes up 28% qoq to 1,088","bullets":["GAAP net loss of $26.2M ($0.29 per share); non-GAAP adjusted loss of $13.8M ($0.15 per share).","EsoGuard test volumes of 1,088 in Q3 2022, up 28% sequentially and 436% YoY.","Cash and equivalents $56.8M at Sep 30, 2022, down from $77.3M at Dec 31, 2021.","Issued $11.25M face value Senior Secured Convertible Note in Sep 2022; proceeds $10.2M.","Veris Cancer Care Platform on track for commercial launch by end 2022; Lucid sales team targeting 58 professionals early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032536","json":"https://secwatch.observer/filing/0001493152-22-032536.json","markdown":"https://secwatch.observer/filing/0001493152-22-032536.md","text":"https://secwatch.observer/filing/0001493152-22-032536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/0001493152-22-032536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:33:00.604433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"004a119ca8772a4a9fbc3db413dee80e8b2c6959","claim":"PAVmed Inc. reported the three months ended September 30, 2022 results: revenue $0.1 million, net income approximately $26.2 million, EPS $(0.29) per common share.","evidence_excerpt":"For the three months ended September 30, 2022, EsoGuard related revenues were $0.1 million. Operating expenses were approximately $23.4 million, which include stock-based compensation expenses of $4.8 million. GAAP net loss attributable to common stockholders was approximately $26.2 million, or $(0.29) per common share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/0001493152-22-032536-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"approximately $26.2 million"},{"label":"EPS","value":"$(0.29) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}